<DOC>
	<DOC>NCT01015144</DOC>
	<brief_summary>The aim of the study was to assess of the influence of atorvastatin on selected indicators of an inflammatory condition, function of the left ventricle and factors affecting the occurrence of undesired events like rehospitalizations and mortality in patients with dilated cardiomyopathy.</brief_summary>
	<brief_title>The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy, Dilated</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>patients 18 years old or older patients who signed informed consent patients with dilated cardiomyopathy (according ESC 2007) patients who had no significant coronary artery stenoses &gt;30% on cardiac catheterization BP â‰¥140/90 lub &lt;90/60 congenital heart disease acquired valvular disease except for mitral incompetence secondary to left ventricular dilatation New York Heart Association (NYHA) functional class IV statin treatment preserved hyperactivity of aminotransferases with unexplained etiology, muscle disorders which might cause druginduced myopathy, uncontrolled diabetes, liver diseases, creatinine level &gt; 2 mg/dl and/or GFR&lt;30ml/min, abuse of alcohol or drugs, chronic inflammatory diseases, pregnancy or lactation, severe hypothyroidism, immunosuppressive treatment, operation or severe injury during last month vaccination during last 3 months heart stimulation device or implantable cardioverter defibrillator or who didn't write conscious consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>atorvastatin</keyword>
	<keyword>dilated cardiomyopathy</keyword>
	<keyword>heart failure</keyword>
	<keyword>inflammation</keyword>
</DOC>